Status:

UNKNOWN

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

Conquer Cancer Foundation

Conditions:

Stage IV Melanoma

Advanced Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer. The intervention is an educational vi...

Detailed Description

This two-part study will 1) refine and 2) pilot test an intervention to improve participant's and caregiver knowledge and increase communication with the oncology team about immunotherapy. * The inte...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • All participants (Patients and Caregivers)-Table 1
  • Age 18 or older
  • Ability to read and respond in English
  • Patient Inclusion Criteria (in addition to Table 1)
  • Receiving care in the MGH Cancer Center
  • Diagnosis of advanced (stage IV) melanoma or advanced, incurable lung cancer, including stage IV non-small cell lung cancer (NSCLC), unresectable stage III NSCLC, extensive-stage small cell lung cancer.
  • Plan to initiate immunotherapy with an ICI (pembrolizumab, nivolumab, ipilimumab, atezolizumab or combination), per clinician documentation in the electronic health record or study staff communication with clinician
  • Caregiver Inclusion Criteria (in addition to Table 1)
  • Identified as "a supportive person involved in their cancer care" by a patient enrolled in the study
  • Exclusion criteria
  • Major psychiatric condition or comorbid illness that prohibits participation in the study
  • Cognitive impairment that prohibits provision of informed consent or participation in the study
  • Pregnant women
  • Prisoners

Exclusion

    Key Trial Info

    Start Date :

    January 23 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    April 1 2024

    Estimated Enrollment :

    210 Patients enrolled

    Trial Details

    Trial ID

    NCT04670445

    Start Date

    January 23 2021

    End Date

    April 1 2024

    Last Update

    October 23 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Massachusetts General Hospital

    Boston, Massachusetts, United States, 02115